US Bancorp DE Boosts Holdings in Laboratory Corp. of America Holdings (LH)

US Bancorp DE raised its position in Laboratory Corp. of America Holdings (NYSE:LH) by 10.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 42,069 shares of the medical research company’s stock after purchasing an additional 3,949 shares during the quarter. US Bancorp DE’s holdings in Laboratory Corp. of America were worth $6,711,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Aperio Group LLC increased its stake in shares of Laboratory Corp. of America by 2.3% in the fourth quarter. Aperio Group LLC now owns 52,287 shares of the medical research company’s stock valued at $8,340,000 after buying an additional 1,190 shares during the period. Boston Partners increased its stake in shares of Laboratory Corp. of America by 13.9% in the fourth quarter. Boston Partners now owns 5,264,025 shares of the medical research company’s stock valued at $839,665,000 after buying an additional 644,355 shares during the period. CIBC World Markets Inc. acquired a new stake in shares of Laboratory Corp. of America in the fourth quarter valued at about $380,000. Iridian Asset Management LLC CT increased its stake in shares of Laboratory Corp. of America by 2.3% in the fourth quarter. Iridian Asset Management LLC CT now owns 1,618,226 shares of the medical research company’s stock valued at $258,123,000 after buying an additional 36,260 shares during the period. Finally, Quantitative Systematic Strategies LLC acquired a new stake in shares of Laboratory Corp. of America in the fourth quarter valued at about $545,000. Hedge funds and other institutional investors own 90.87% of the company’s stock.

In other news, Director Adam H. Schechter sold 1,263 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $169.29, for a total value of $213,813.27. Following the transaction, the director now owns 7,297 shares in the company, valued at $1,235,309.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.90% of the stock is owned by company insiders.

Shares of Laboratory Corp. of America Holdings (LH) opened at $168.08 on Friday. The company has a quick ratio of 1.75, a current ratio of 1.31 and a debt-to-equity ratio of 0.93. Laboratory Corp. of America Holdings has a one year low of $133.65 and a one year high of $181.71. The company has a market capitalization of $16,843.83, a P/E ratio of 17.24, a price-to-earnings-growth ratio of 1.45 and a beta of 0.93.

Laboratory Corp. of America (NYSE:LH) last announced its quarterly earnings data on Tuesday, February 6th. The medical research company reported $2.45 EPS for the quarter, beating the Zacks’ consensus estimate of $2.38 by $0.07. Laboratory Corp. of America had a return on equity of 16.30% and a net margin of 12.15%. The firm had revenue of $2.70 billion during the quarter, compared to analysts’ expectations of $2.70 billion. During the same quarter last year, the firm posted $2.15 earnings per share. The company’s revenue for the quarter was up 13.2% compared to the same quarter last year. equities research analysts expect that Laboratory Corp. of America Holdings will post 11.52 EPS for the current fiscal year.

LH has been the subject of several recent research reports. Barclays increased their price target on Laboratory Corp. of America from $183.00 to $190.00 and gave the company an “overweight” rating in a research note on Thursday, October 26th. Zacks Investment Research cut Laboratory Corp. of America from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Jefferies Group set a $167.00 price target on Laboratory Corp. of America and gave the company a “hold” rating in a research note on Friday, November 24th. Deutsche Bank raised their target price on Laboratory Corp. of America from $170.00 to $172.00 and gave the stock a “buy” rating in a research note on Thursday, October 26th. Finally, Mizuho set a $178.00 target price on Laboratory Corp. of America and gave the stock a “hold” rating in a research note on Wednesday, January 24th. Six equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $180.73.

ILLEGAL ACTIVITY NOTICE: “US Bancorp DE Boosts Holdings in Laboratory Corp. of America Holdings (LH)” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.com-unik.info/2018/02/10/us-bancorp-de-boosts-holdings-in-laboratory-corp-of-america-holdings-lh.html.

Laboratory Corp. of America Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corp. of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit